دورية أكاديمية
أعرض في EDS

Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.

التفاصيل البيبلوغرافية
العنوان: Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
المؤلفون: Lee K; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea., Lee J; Brain Korea 21 Plus Project for Biomedical Science, Korea University College of Medicine, Seoul, Korea.; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea., Choi J; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.; Department of Genetics, Yale University School of Medicine, New Haven, CT, USA., Sim SH; Center for Breast Cancer, National Cancer Center, Goyang, Korea., Kim JE; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Kim MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Park YH; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea., Koh SJ; Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Korea., Park KH; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea., Kang MJ; Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea., Ahn MS; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea., Lee KE; Department of Hematology and Oncology, Ewha Womans University Hospital, Seoul, Korea., Kim HJ; Division of Hematology/Medical Oncology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea., Ahn HK; Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea., Kim HJ; Division of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea., Park KU; Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea., Park IH; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. parkih@korea.ac.kr.
المصدر: Scientific reports [Sci Rep] 2023 Jun 19; Vol. 13 (1), pp. 9928. Date of Electronic Publication: 2023 Jun 19.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Circulating Tumor DNA*/genetics, Humans ; Female ; Trastuzumab/therapeutic use ; Genomics ; Mutation ; Class I Phosphatidylinositol 3-Kinases/genetics ; Biomarkers, Tumor/genetics
مستخلص: We explored accumulated genomic alterations in patients with heavily treated HER2 + metastatic breast cancer enrolled in the KCSG BR18-14/KM10B trial. Targeted sequencing was performed with circulating tumor DNAs (ctDNAs) collected before the treatment of 92 patients. ctDNAs collected at the time of disease progression from seven patients who had a durable response for > 12 months were also analyzed. Sixty-five genes were identified as pathogenic alterations in 99 samples. The most frequently altered genes were TP53 (n = 48), PIKCA (n = 21) and ERBB3 (n = 19). TP53 and PIK3CA mutations were significantly related with shorter progression free survival (PFS), and patients with a higher ctDNA fraction showed a worse PFS. The frequency of homologous recombination deficiency (HRD)-related gene mutations was higher than that in matched tumor tissues, and these mutations tended to be associated with shorter PFS. New pathogenic variants were found at the end of treatment in all seven patients, including BRCA2, VHL, RAD50, RB1, BRIP1, ATM, FANCA, and PIK3CA mutations. In conclusion, TP53 and PIK3CA mutations, as well as a higher ctDNA fraction, were associated with worse PFS with trastuzumab and cytotoxic chemotherapy. The enrichment of HRD-related gene mutations and newly detected variants in ctDNA may be related to resistance to treatment.
(© 2023. The Author(s).)
References: Sci Rep. 2017 Apr 3;7(1):583. (PMID: 28373672)
ESMO Open. 2021 Oct;6(5):100230. (PMID: 34479035)
J Clin Oncol. 2020 Dec 10;38(35):4184-4193. (PMID: 33095682)
Nat Rev Genet. 2019 Feb;20(2):71-88. (PMID: 30410101)
Nat Med. 2019 Sep;25(9):1415-1421. (PMID: 31501609)
Clin Cancer Res. 2023 Apr 14;29(8):1569-1581. (PMID: 36730339)
Cell Death Discov. 2020 Oct 10;6:100. (PMID: 33083021)
EBioMedicine. 2018 Jun;32:111-118. (PMID: 29807833)
Nat Genet. 2019 Oct;51(10):1450-1458. (PMID: 31570896)
Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. (PMID: 32444418)
Int J Cancer. 2020 Mar 1;146(5):1359-1368. (PMID: 31241775)
Oncotarget. 2016 Oct 4;7(40):65364-65373. (PMID: 27588476)
Nat Commun. 2021 Apr 23;12(1):2423. (PMID: 33893289)
Ann Oncol. 2019 Jun 1;30(6):945-952. (PMID: 30860573)
Ann Oncol. 2021 Dec;32(12):1475-1495. (PMID: 34678411)
Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. (PMID: 28760909)
Ann Oncol. 2023 Jan;34(1):111-120. (PMID: 36208697)
Mol Cancer. 2021 Nov 29;20(1):151. (PMID: 34839818)
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-14. (PMID: 32213086)
Nat Commun. 2020 Nov 4;11(1):5584. (PMID: 33149131)
Cancer. 2018 Mar 1;124(5):1061-1069. (PMID: 29178133)
Cancer Med. 2022 Jul;11(14):2767-2778. (PMID: 35393784)
J Oncol. 2020 Aug 27;2020:4259293. (PMID: 32908507)
Cancer Res Treat. 2021 Jan;53(1):123-130. (PMID: 32810930)
Mol Cancer Ther. 2017 Jul;16(7):1412-1420. (PMID: 28446639)
Endocr Relat Cancer. 2020 Mar;27(3):153-162. (PMID: 31905165)
Cancer Res Treat. 2022 Jan;54(1):30-39. (PMID: 34015890)
Breast. 2022 Oct;65:172-178. (PMID: 36029565)
ESMO Open. 2022 Feb;7(1):100343. (PMID: 34995893)
Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):. (PMID: 28289245)
Pathobiology. 2017;84(6):292-305. (PMID: 29131018)
Int J Mol Sci. 2021 Dec 29;23(1):. (PMID: 35008774)
Nat Commun. 2016 Jul 13;7:12222. (PMID: 27406316)
J Cancer Res Clin Oncol. 2017 Jul;143(7):1255-1262. (PMID: 28247034)
Cancer Treat Rev. 2022 May;106:102384. (PMID: 35366566)
Sci Rep. 2020 Jul 29;10(1):12728. (PMID: 32728097)
Breast. 2022 Oct;65:116-123. (PMID: 35926241)
J Natl Compr Canc Netw. 2021 May 01;19(5):484-493. (PMID: 34794122)
Int J Cancer. 2020 Mar 1;146(5):1445-1456. (PMID: 31340061)
Nat Commun. 2017 Apr 20;8:14944. (PMID: 28429735)
Blood Adv. 2020 Aug 11;4(15):3550-3557. (PMID: 32761230)
Blood Cancer Discov. 2021 May;2(3):226-237. (PMID: 34027416)
Cancer Res Treat. 2023 Apr;55(2):531-541. (PMID: 36097803)
Ther Adv Med Oncol. 2022 Sep 26;14:17588359221110162. (PMID: 36188485)
Clin Cancer Res. 2021 Jun 1;27(11):3094-3105. (PMID: 33558422)
J Transl Med. 2022 May 13;20(1):211. (PMID: 35562750)
Ther Adv Med Oncol. 2021 May 06;13:17588359211012982. (PMID: 33995598)
Br J Cancer. 2014 Jan 21;110(2):363-8. (PMID: 24231948)
JCO Precis Oncol. 2022 Mar;6:e2100370. (PMID: 35357905)
المشرفين على المادة: 0 (Circulating Tumor DNA)
P188ANX8CK (Trastuzumab)
EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20230619 Date Completed: 20230621 Latest Revision: 20230701
رمز التحديث: 20230701
مُعرف محوري في PubMed: PMC10279711
DOI: 10.1038/s41598-023-35925-8
PMID: 37336919
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا